Formycon AG (XTER:FYB) Other Net Income (Loss) : €-0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Other Net Income (Loss)?

Formycon AG's Other Net Income (Loss) for the six months ended in Dec. 2023 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.00 Mil.

Formycon AG's quarterly Other Net Income (Loss) declined from Dec. 2022 (€0.00 Mil) to Jun. 2023 (€-0.00 Mil) but then increased from Jun. 2023 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Formycon AG's annual Other Net Income (Loss) declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Formycon AG Other Net Income (Loss) Historical Data

The historical data trend for Formycon AG's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Other Net Income (Loss) Chart

Formycon AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Formycon AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Formycon AG Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00 Mil.

Formycon AG Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Formycon AG's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG (XTER:FYB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

FYB:Germany FYB:Germany FYB:Germany

Address

Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.formycon.com

Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.

Executives

Dr. Stefan Glombitza	Board of Directors
Dr. Carsten Brockmeyer	Board of Directors
Dr. Nicolas Combé	Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines